Man in remission from blood cancer and HIV after remarkable treatment
Paul Edmonds of California is fifth-known person in world confirmed to be in remission from both, says cancer instituteDoctors say a man inCalifornia who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.Paul Edmonds is only the fifth-known person in the world confirmed to be in remission for both acute myelogenous leukemia and HIV, according to a recentnews release from City of Hope, the national cancer institute that provided his medical care.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 28, 2024 Category: Science Authors: Ramon Antonio Vargas Tags: US news Infectious diseases Medical research Aids and HIV Cancer research California World news Science Source Type: news

Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
WEDNESDAY, Feb. 21, 2024 -- For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the February issue of Leukemia Research. Hannah Goulart,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2024 Category: Pharmaceuticals Source Type: news

Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML
(MedPage Today) -- A 68-year-old man with HIV-1 who underwent hematopoietic cell transplant (HCT) for acute myelogenous leukemia 5 years ago has been free of HIV infection for 35 months after stopping antiretroviral treatment (ART), according to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 15, 2024 Category: Hematology Source Type: news

Development of CAR-T Cells for T-ALL Targeting CCR9, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL). CCR9 is a potential cancer immunotherapy target, expressed in the majority of cases of T-ALL but... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2024 Category: Pharmaceuticals Tags: FVT TRI Source Type: news

FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia
(MedPage Today) -- Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and chemotherapy, a preliminary... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 13, 2024 Category: Hematology Source Type: news

Drug Trials Snapshots: REZLIDHIA
REZLIDHIA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation when the disease has come back (relapsed) or has not improved after one or more treatments (refractory). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 30, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Risk for Cancer Increased for Relatives of Patients With Leukemia
THURSDAY, Jan. 18, 2024 -- Relatives of patients with myelodysplastic neoplasia (MDS), acute myeloid leukemia (AML), or acute lymphoblastic leukemia (ALL) have an increased risk for cancer, according to a study published in the February issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2024 Category: Pharmaceuticals Source Type: news

Molecular & #039;super-glue & #039; shows promise of cancer drug discovery platform
Today, St. Jude Children's Research Hospital scientists published their work on SJ3149, a compound with broad activity against many cancer types, particularly acute myeloid leukemia (AML). SJ3149 sticks to the cancer-related protein casein kinase 1 alpha (CK1α), leading to its destruction. The findings were reported in Nature Communications. (Source: World Pharma News)
Source: World Pharma News - January 16, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

What Prompts a Post-Childhood'Survival Cliff' in ALL? What Prompts a Post-Childhood'Survival Cliff' in ALL?
Experts explore why children with acute lymphoblastic leukemia fare well with current treatment options, while adolescents and younger adults still face high mortality rates.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 10, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

First ALL Treatment Guidance for Young Patients in the Works First ALL Treatment Guidance for Young Patients in the Works
: The American Society of Hematology is developing the first clinical practice guidelines for treating acute lymphocytic leukemia in adolescents and young adults.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 9, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Advances in Acute Lymphoblastic Leukemia From ASH 2023 Advances in Acute Lymphoblastic Leukemia From ASH 2023
Chemotherapy-free regimens in Philadelphia chromosome –positive acute lymphoblastic leukemia and optimization of combination therapies are among advances from ASH 2023 chosen by Dr Hagop Kantarjian.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news

Allogeneic HCT After Primary Induction Failure Beneficial in Leukemia
THURSDAY, Dec. 21, 2023 -- For patients with acute myeloid leukemia (AML), immediate allogeneic hematopoietic stem cell transplantation (HCT) after primary induction failure (PIF) offers long-term survival benefit, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2023 Category: Pharmaceuticals Source Type: news

Peripheral Blood Haplo-SCT Feasible for Leukemia Patients 70 Years and Older
WEDNESDAY, Dec. 20, 2023 -- For patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a nonmyeloablative conditioning regimen (NMAC) is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2023 Category: Pharmaceuticals Source Type: news

Why Is Shattuck Labs (STTK) Stock Up 93% Today?
Shattuck Labs (NASDAQ:STTK) stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from an ongoing Phase 1a/b trial. These clinical trials cover the use of SL-172154 in combination with azacitidine in HR-MDS and TP53m Acute Myeloid Leukemia (AML) patients.…#shattucklabs #phase1a #acutemyeloidleukemia #aml #linipandite #sttk #palantirtechnologies #pltr #reshapelifesciences #williamwhite (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2023 Category: Consumer Health News Source Type: news

Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia
(MedPage Today) -- SAN DIEGO -- Nearly two-thirds of patients with relapsed or refractory KMT2A-rearranged acute leukemia responded to an investigational oral menin inhibitor, a phase II trial showed. Among 57 children and adults in the pivotal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2023 Category: Hematology Source Type: news